Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Rosati
Gerardo
G
Medical Oncology Unit, San Carlo Hospital, Potenza, Italy. rosatiger@yahoo.com
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004264:DNA Topoisomerases, Type I / Q000627:therapeutic use*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D000077146:Irinotecan; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077146:Irinotecan; D004264:DNA Topoisomerases, Type I; D000068818:Cetuximab; D002166:Camptothecin